Cytokinetics, Inc.
Cytokinetics Grants Exclusive License to Bayer for Aficamten in Japan
Summary
On November 18, 2024, Cytokinetics, Incorporated announced an exclusive license agreement with Bayer Consumer Care AG for the development and commercialization of its cardiac sarcomere inhibitor, aficamten, in Japan. Cytokinetics will receive an upfront payment of €50 million and is eligible for up to €580 million in additional milestone payments and royalties based on Bayer's net sales and achievement of certain clinical and commercial milestones.
Profitelligence Alerts
Get alerts for CYTK
Be first to know when Cytokinetics, Inc. files with the SEC.
Filing Categories
Advertisement
About Cytokinetics, Inc.
Cytokinetics, Inc. is a biopharmaceutical company focused on the discovery, development, and commercialization of novel muscle activators as potential treatments for debilitating diseases. Primarily, the company's work aims to address unmet medical needs in the fields of neurology and cardiology, offering therapeutic solutions that target muscle function. Cytokinetics' research centers on small molecule drugs that modulate muscle performance, which could significantly aid patients suffering from heart failure, amyotrophic lateral sclerosis (ALS), and other muscle-related conditions. The company is actively involved in clinical trials and collaborates with other notable entities in its quest for innovative medical advancements. Its contributions to the healthcare sector exemplify the growing role of targeted therapy in improving patient outcomes. Headquartered in South San Francisco, California, Cytokinetics operates as a key player in the biotechnology landscape, with a commitment to pioneering treatments that leverage the complex mechanisms of muscle biology.
Official SEC Documents
Advertisement